• kortere tid til tumorudvikling hos patienter med fremskreden hoved - og halscancer, som au modtager strålebehandling, når det indgives for at behandle en hæmoglobinkoncentration på mere end 14 g/ dl (8, 7 mmol/ l).
au shortened time to tumour progression in patients with advanced head and neck cancer receiving radiation therapy when administered to target a haemoglobin of greater than 14 g/ dl (8.7 mmol/ l), ESAs are not indicated for use in this patient population.